Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Radiation and ADT in Gleason Group 5 Prostate Cancer
NCT03543189Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2018
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in prostate cancer (PCa), sponsored by Moffitt Cancer Center. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03543189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543189.